Dr Rakesh Dixit | Vice President R&D, Global Head, Biologics Safety Assessment
MedImmune Inc | United States

Dr Rakesh Dixit, Vice President R&D, Global Head, Biologics Safety Assessment, MedImmune Inc

Dr. Dixit is a Vice Preseident (R &D) & Global Head of Biologics Safety Assessment, Pathology, and Laboratory Animal Medicine. At MedImmune, an AstraZeneca Biologics R &D company.  In his current position as a Vice President of R &D, and Global Head of Biologics Safety Assessment, including toxicology, pathology and LAR,  Rakesh is responsible for providing guidance on research and development of biological products; including nonclinical toxicology/safety support for all AstraZeneca-MedImmune biologics products, including monoclonal antibodies and vaccines.  Rakesh has published more than 60 papers in renowned international journals and has given over 100 invited lectures/presentations/workshops in national and international meetings.  
 
Rakesh’s areas of expertise are mainly in the area of pharmaceuticals and biologics drug development, safety assessment of small molecule drugs, biologics, vaccines and in exploring mechanisms of toxicity and biologics pharmacological activity.  Rakesh has helped to bring several blockbuster pharmaceuticals to the market while working at Merck. Rakesh a recognized expert in safety and pharmacology biomarkers and their applications..  Rakesh is the Editor-in-chief of Toxicology Mechanisms and Methods and Associate Editor for Toxicology Applied Pharmacology, and Journal of Toxicology and Environmental Health. Rakesh also serves as an expert reviewer and in appointed committee for many programs managed by the prestigious U.S. National Academy of Sciences and US National Institutes of Health, including National Cancer Institute.

Appearances:



DC Co-conference Day 2 April 4 @ 09:40

Panel Discussion: challenges to enhancing the therapeutic effectiveness of immune checkpoint antagonists with checkpoint agonists and inhibitors of immuno-metabolic pathways

  • Activating the antitumor immune T cell response through agonistic targets such as CD137 and OX40
  • Understanding the pathways used to create immune suppression and techniques to slow down immune suppression
  • What makes t-cell agonists so hard to work with vs checkpoint inhibitors?

back to speakers